Three is the magic number after biotech firm Orphazyme has halved its board of directors, which used to count six people, the firm reports in a press release.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
USA prepares to drop public health emergency status for mpox
The US Health Authorities are ready to declare the public emergency over as cases of mpox, formerly known as monkeypox, plummet.
Ambu, Coloplast and GN helped by relaxation of China's covid policy
The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Head of Engineering 
QA Specialist 
Nordic Medical Manager, Central Nervous System 
Laboratory assistants for an exciting QC department 
Head Of Business Unit Pharma, Öresund Region, AFRY 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Research Scientist (maternity cover) 
Supply Chain Manager 
Chief consultant for Dansk Erhvervs Health and life science 
Systems Verification Manager for Embedded Medical Solutions 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market